Get the Stockscreener App
7.83
3.57%
-0.29
After Hours:
7.98
0.15
+1.92%
Gyre Therapeutics Inc stock is traded at $7.83, with a volume of 74,841.
It is down -3.57% in the last 24 hours and up +3.57% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$8.12
Open:
$8.15
24h Volume:
74,841
Relative Volume:
0.61
Market Cap:
$754.13M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
83.74
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+1.82%
1M Performance:
+3.57%
6M Performance:
-32.90%
1Y Performance:
-42.97%
1-Day Range:
$7.80
$8.2822
1-Week Range:
$7.55
$8.555
52-Week Range:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.83 | 742.05M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Will Gyre Therapeutics Inc. bounce back from current supportFed Meeting & Reliable Price Breakout Signals - Newser
Evaluating Gyre Therapeutics Inc. with trendline analysisJuly 2025 Highlights & Technical Entry and Exit Alerts - Newser
how high can gyre therapeutics inc. stock goMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
How to use Fibonacci retracement on Gyre Therapeutics Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Is it time to cut losses on Gyre Therapeutics Inc.July 2025 Short Interest & Low Risk Growth Stock Ideas - Newser
How high can Gyre Therapeutics Inc. stock goWeekly Trade Review & Community Consensus Stock Picks - Newser
Full technical analysis of Gyre Therapeutics Inc. stock2025 Year in Review & Verified Stock Trade Ideas - Newser
Gyre Therapeutics Inc. stock prediction for this weekMarket Sentiment Report & Technical Analysis for Trade Confirmation - Newser
What earnings revisions data tells us about Gyre Therapeutics Inc.Portfolio Value Report & Stock Portfolio Risk Control - Newser
Multi asset correlation models including Gyre Therapeutics Inc.Weekly Investment Report & Weekly Top Gainers Alerts - Newser
Gyre Therapeutics Inc. stock volume spike explainedJuly 2025 Analyst Calls & Free Daily Entry Point Trade Alerts - Newser
What is Noble Financial's Forecast for GYRE Q1 Earnings? - MarketBeat
Can machine learning forecast Gyre Therapeutics Inc. recoveryPortfolio Risk Summary & Reliable Entry Point Trade Alerts - Newser
Intraday pattern recognizer results for Gyre Therapeutics Inc.2025 Trading Recap & Daily Entry Point Trade Alerts - Newser
Is Gyre Therapeutics Inc. stock reversal real or fakeJuly 2025 Recap & Technical Pattern Based Buy Signals - Newser
Price action breakdown for Gyre Therapeutics Inc.Market Growth Report & Comprehensive Market Scan Reports - Newser
Applying sector rotation models to Gyre Therapeutics Inc.Trade Ideas & High Accuracy Swing Entry Alerts - Newser
Will Gyre Therapeutics Inc. see short term momentumEarnings Trend Report & Growth Focused Stock Reports - Newser
Live market analysis of Gyre Therapeutics Inc.Wall Street Watch & Technical Entry and Exit Alerts - Newser
What Fibonacci levels say about Gyre Therapeutics Inc. reboundLong Setup & Weekly Top Gainers Alerts - Newser
Published on: 2025-09-11 00:43:22 - Newser
Q1 Earnings Forecast for GYRE Issued By Noble Financial - Defense World
Gyre Therapeutics Inc. stock momentum explainedQuarterly Trade Report & Daily Market Momentum Tracking - Newser
Sentiment analysis tools applied to Gyre Therapeutics Inc.July 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Gyre Therapeutics : H.C. Wainwright Global Investment Conference Presentation – September 2025 916.4 KB - MarketScreener
Gyre Therapeutics (GYRE) Receives a Buy from Noble Financial - The Globe and Mail
Using portfolio simulators with Gyre Therapeutics Inc. included2025 Support & Resistance & Daily Profit Maximizing Trade Tips - Newser
Pattern recognition hints at Gyre Therapeutics Inc. upsideCEO Change & Entry Point Confirmation Signals - Newser
Combining machine learning predictions for Gyre Therapeutics Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
Building trade automation scripts for Gyre Therapeutics Inc.Market Performance Report & Precise Buy Zone Tips - Newser
Is Gyre Therapeutics Inc. meeting your algorithmic filter criteriaEarnings Overview Report & Weekly Watchlist of Top Performers - Newser
Technical analysis overview for Gyre Therapeutics Inc. stock2025 Fundamental Recap & Consistent Profit Alerts - Newser
Published on: 2025-09-10 00:46:07 - Newser
Gyre Therapeutics Inc. stock trendline breakdownMarket Trend Review & Weekly Momentum Stock Picks - Newser
Does Gyre Therapeutics Inc. offer margin of safetyJuly 2025 Rallies & Daily Risk Controlled Trade Plans - Lancaster City Council
How do insiders feel about Gyre Therapeutics Inc.Earnings Beat & Daily Price Action Insights - Lancaster City Council
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):